Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin Maintenance vs Observation in Advanced STS
NCT02929394Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Trabectedin with Observation (2 arms). Primary endpoint: Progression-Free Survival. Started Nov 2017; status: terminated.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02929394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929394.